Checking heart access after the evolut fx plus tavi valve
Part of Heart & circulation clinical trials.
This study is looking at how well doctors can reach the coronary arteries (the blood vessels that supply the heart muscle) after a TAVI procedure using the Evolut FX Plus valve. It may help improve future procedures for people with severe aortic stenosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 years of age or older.
- You have severe aortic stenosis (a narrowing of the heart's main valve).
- You are scheduled to receive the Evolut FX Plus valve during a TAVI procedure.
- You can undergo a CT scan of your heart with contrast dye before the procedure.
- You have no history of a previous aortic valve replacement (surgical or catheter-based).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks whether an “investigational” transcatheter aortic valve is safe and works well for people with severe, calcified aortic stenosis (a stiff, narrowed heart valve). It may help improve valve function and symptoms, but you must meet specific heart, scan, and health-status requirements.
This trial compares two approaches for replacing a tight aortic heart valve (TAVI) through a leg artery: doing it with or without a routine check of your heart's arteries (coronary angiogram). If you have severe aortic stenosis and are scheduled for TAVI, this study helps find out whether skipping the artery check is safe and effective.
This trial tests whether using a special CT scan (CT-FFR) to guide treatment improves outcomes for people with severe aortic stenosis (a narrowed heart valve). It may help doctors decide between valve replacement surgery or a less invasive procedure.
This trial is testing a new heart valve system (Medtronic Evolut FX+) for people with severe aortic stenosis—a condition where the heart's main valve is narrowed. The study aims to see how well the valve works and improve your care journey.
This trial studies whether a new through-the-blood-vessel heart valve (TAVR) is safe and works well for people with severe aortic stenosis who are too risky for traditional surgery. If you qualify, you would be closely followed to check your symptoms and valve function over time.
This trial compares two newer types of replacement heart valves (SAPIEN 3 Ultra Resilia and Evolut FX) to see which one works better for people with severe aortic stenosis, a condition where the heart's main valve becomes narrow. If you join, you'll be randomly assigned to receive one of the two valves during your TAVI procedure.
Hear when a new Severe Aortic Stenosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.